SlideShare a Scribd company logo
1 of 3
Joy A. Awoniyi
                                                                                          Ambulatory Care Rotation
                                                                                       Preceptor: Dr. Daryl Norwood


                                        Diabetes Case
Presentation
R.C is a 57-year-old man with Type 2 diabetes first diagnosed two years ago. Other medical problems include
obesity and hypothyroidism. He has a history of heavy alcohol use but quit drinking alcohol 2 years ago. He
presents now for routine follow-up and is noted to have a blood pressure of 168/100 mmHg. He is
asymptomatic.
Physical exam reveals a height of 5’8” (172cm), weight of 243 pounds (110kg), blood pressure of 160/100
mmHg, and a regular pulse of 84 beats per minute. There is no retinopathy or thyromegaly. There is no clinical
evidence of congestive heart failure or peripheral vascular disease.
Laboratory evaluation reveals trace protein on urinalysis, a low-density lipoprotein (LDL) cholesterol level of 134
mg/dL, a high-density lipoprotein (HDL) cholesterol level of 35mg/dL, a triglyceride level of 460mg/dL and a total
cholesterol level of 240 mg/dL, blood urea nitrogen of 14mg/dL, serum creatinine of 1.2mg/dL, random serum
glucose of 192 mg/dL, a glycosylated hemoglobin level of 9.5%, normal electrolytes, and normal thyroid-
stimulating hormone levels. A 24-hour urine collection reveals a urinary albumin excretion rate of 250mg daily.



Subjective and Objective Findings
        Patient is asymptomatic
        PMH of alcohol abuse (quit 2 years ago), obesity, and hypothyroidism
        Pertinent vital signs and Lab Values
            o Blood Pressure: 168/100
            o Regular pulse: 84 bpm
            o Serum Creatinine: 1.2mg/dL
                      Creatinine Clearance calculated at 105.6mL/min or 65.7mL/min (Based on ABW and
                          IBW, respectively)
            o BMI was calculated to be 36.94kg/m2
                      Possible relation to hypothyroidism
            o Albumin excretion of 250mg/day (normal levels between 50 and 80mg/24hrs)
            o LDL: 134 mg/dL
        Diagnostic Tests: HgA1C of 9.5%


Assessment
        Related Complications
            o High blood pressure
            o Dyslipidemia
            o Nephropathy manifested as proteinuria
        Risk Factors
            o Obesity (BMI greater than 25)
            o A1C >/= 5.7%
            o Blood pressure >/= 140/90; Hypertension
        Therapeutic Goals
            o Tight glycemic control:Reduce A1C to less than 7% without causing hypoglycemia
            o Prevention of cardiovascular disease

                                                                            Diabetes Case SOAP              1
 Goal blood pressure for patients with diabetes is <130/<80
                     Reduce CVD risks by maintaining healthy cholesterol levels. LDL goal should be <100
        No current medications were mentioned. There is a need for therapy in order to lower A1C and manage
        the patient’s diabetes and related conditions.


Plan
Further Tests and Work-Up
        Liver function tests
        Repeat blood pressure to confirm hypertension
        CBC to rule out and monitor for infections
        More detailed history needed
            o List of medications (current and failed therapies)
            o Family history
            o Previous immunizations
            o Medication Regimen adherence and barriers to adherence

Treatment Recommendation:
To manage his diabetes, I recommend that the patient be started on Metformin 500mg once daily in addition
tothe initiation of lifestyle modifications. This dose may be increased to twice daily dosing as needed or as
tolerated every 1-2 weeks with a maximum dose of 2 grams daily. In the management of diabetes for this
patient, drugs that may cause the patient to gain weight should be avoided.

The patient’s blood pressure should be managed with an ACE Inhibitor such as Lisinopril 10mg daily. Once daily
dosing would be ideal and his choice of ACE-inhibitor should be related to the price for the patient as most ACE
inhibitors exhibit similar profiles. Hydrochlorothiazide may be added for additional control and numerous
preparations are available as combinations of ACE-inhibitors and thiazide diuretics. A beta-blocker is not
recommended at this point in therapy due to the masking of hypoglycemia that may accompany a new diabetes
regimen.

Drug therapy is also recommended for this patient to control cholesterol since the values are above 130. A
reduction of LDL to 99 from 134 is a 26.11% reduction. In a comparison evaluating multiple trials with endpoints
to reduce cardiovascular disease risks in patients with diabetes, Simvastatin appears to have showed the most
benefit in the 4S-DM study where doses between 20 and 40mg daily demonstrated an absolute risk reduction of
42.5% and LDL reduction of 36%. Simvastatin 20mg daily is recommended as initial treatment for this patient.

Although diabetics are prone to increase in clot formation, Aspirin daily is not recommended at this point in
therapy for this particular patient. He is not as high risk and has no evidence of CHF or peripheral vascular
disease.

Goals and Monitoring Parameters
       Metformin use requires routine monitoring of liver function tests and serum creatinine. The urine
       should also be monitored for glucose and ketones.
       ACE inhibitor therapy requires monitoring of electrolyte levels (potassium, in particular), blood pressure,
       renal function, and BUN.
       Simvastatin use warrants the monitoring of LFTs, as well as Creatinine Kinase, which is indicative of
       myopathies associated with the medication.


2    Diabetes SOAP Case
Joy A. Awoniyi
                                                                                         Ambulatory Care Rotation
                                                                                      Preceptor: Dr. Daryl Norwood
        Weight changes should be monitored to assess the need for more aggressive treatments or diet
        restriction.
        Monitor Carbohydrate and fat intake. Total fat should be less than 7% of the total calories.
        Target Levels:
            o A1C  Less than 7% Monitor every 2-3 months.
            o Blood pressure  Less than 130/80 Monitor at every routine visit
            o LDL  Less than 100 Lipid assessments may be repeated every 1-2 years
        Routine tests should be performed to evaluate the efficacy of therapy as well as to monitor the
        progression of diabetes to prevent further complications
            o Eye exams annually
            o Serum creatinine at least annually
            o Foot examination
            o Screening for neuropathies

Patient Counseling
        To reduce GI side effects, take metformin with food.
        Avoid drinking alcohol. In addition to its contributions to hyperglycemia, alcohol has a negative
        interaction on the drugs Metformin and Simvastatin that can cause liver toxicities.
        To achieve adequate control of diabetes, lifestyle modifications are an important part of therapy.
        Dietary restrictions, increase in physical activity, and gradual weight loss will be more beneficial than
        taking medication, alone.
            o Exercise should include aerobic activities, such as swimming, walking, or running, at least 3 days
                during each week.




                                                                           Diabetes Case SOAP              3

More Related Content

What's hot

Management of Hyperlipidemia
Management of HyperlipidemiaManagement of Hyperlipidemia
Management of HyperlipidemiaHealth Forager
 
a case study on peptic ulcer
 a case study on peptic ulcer a case study on peptic ulcer
a case study on peptic ulcermartinshaji
 
A CASE PRESENTATION ON GERD ( GASTROESOPHAGEAL REFLUX DISEASE)
A CASE PRESENTATION ON GERD ( GASTROESOPHAGEAL REFLUX DISEASE)A CASE PRESENTATION ON GERD ( GASTROESOPHAGEAL REFLUX DISEASE)
A CASE PRESENTATION ON GERD ( GASTROESOPHAGEAL REFLUX DISEASE)Rajnandini Singha
 
Clinical case study of Alcoholic Liver Disease by Rajendra Keshkar
Clinical case study of  Alcoholic Liver Disease by Rajendra Keshkar Clinical case study of  Alcoholic Liver Disease by Rajendra Keshkar
Clinical case study of Alcoholic Liver Disease by Rajendra Keshkar Dr Rajendra Felix
 
Case on Heart failure with Type 2 Diabetes mellitus
Case on Heart failure with Type 2 Diabetes mellitusCase on Heart failure with Type 2 Diabetes mellitus
Case on Heart failure with Type 2 Diabetes mellitusDr. Abhimanyu Prashar
 
Myocardial infraction by satyavardhan pharm.d
Myocardial infraction by satyavardhan pharm.dMyocardial infraction by satyavardhan pharm.d
Myocardial infraction by satyavardhan pharm.dSatya satyanittu4
 
Case presentation on ALD with PORTAL HTN
Case presentation on ALD with PORTAL HTN Case presentation on ALD with PORTAL HTN
Case presentation on ALD with PORTAL HTN BINDU MADHAVI
 
Case presentation on hypothyroidism
Case presentation on hypothyroidismCase presentation on hypothyroidism
Case presentation on hypothyroidismDr. Shazia Afreen
 
CASE PRESENTATION ON DIABETES MELLITUS
CASE PRESENTATION ON DIABETES MELLITUSCASE PRESENTATION ON DIABETES MELLITUS
CASE PRESENTATION ON DIABETES MELLITUSvarshawadnere
 
Case presentation on Alcoholic liver disease
Case presentation on Alcoholic liver diseaseCase presentation on Alcoholic liver disease
Case presentation on Alcoholic liver diseaseHAMMADKC
 
case ppt on UTI with IBD
case ppt on UTI with IBDcase ppt on UTI with IBD
case ppt on UTI with IBDDr B Naga Raju
 
14. a case study on diabetes mellitus type 1 with diabetic ketoacidosis cp in...
14. a case study on diabetes mellitus type 1 with diabetic ketoacidosis cp in...14. a case study on diabetes mellitus type 1 with diabetic ketoacidosis cp in...
14. a case study on diabetes mellitus type 1 with diabetic ketoacidosis cp in...Dr. Ajita Sadhukhan
 
Case Studies Clinical pharmacy
Case Studies Clinical pharmacyCase Studies Clinical pharmacy
Case Studies Clinical pharmacyQurat Ul Ain
 

What's hot (20)

case study on HYPOTHYROIDISM
case study on HYPOTHYROIDISMcase study on HYPOTHYROIDISM
case study on HYPOTHYROIDISM
 
Soap format
Soap formatSoap format
Soap format
 
viral hepatitis
viral hepatitis viral hepatitis
viral hepatitis
 
A CASE PRESENTATION ON ALCOHOLIC LIVER DISEASE
A CASE PRESENTATION ON ALCOHOLIC LIVER DISEASEA CASE PRESENTATION ON ALCOHOLIC LIVER DISEASE
A CASE PRESENTATION ON ALCOHOLIC LIVER DISEASE
 
Management of Hyperlipidemia
Management of HyperlipidemiaManagement of Hyperlipidemia
Management of Hyperlipidemia
 
a case study on peptic ulcer
 a case study on peptic ulcer a case study on peptic ulcer
a case study on peptic ulcer
 
A CASE PRESENTATION ON GERD ( GASTROESOPHAGEAL REFLUX DISEASE)
A CASE PRESENTATION ON GERD ( GASTROESOPHAGEAL REFLUX DISEASE)A CASE PRESENTATION ON GERD ( GASTROESOPHAGEAL REFLUX DISEASE)
A CASE PRESENTATION ON GERD ( GASTROESOPHAGEAL REFLUX DISEASE)
 
Clinical case study of Alcoholic Liver Disease by Rajendra Keshkar
Clinical case study of  Alcoholic Liver Disease by Rajendra Keshkar Clinical case study of  Alcoholic Liver Disease by Rajendra Keshkar
Clinical case study of Alcoholic Liver Disease by Rajendra Keshkar
 
Case on Heart failure with Type 2 Diabetes mellitus
Case on Heart failure with Type 2 Diabetes mellitusCase on Heart failure with Type 2 Diabetes mellitus
Case on Heart failure with Type 2 Diabetes mellitus
 
Myocardial infraction by satyavardhan pharm.d
Myocardial infraction by satyavardhan pharm.dMyocardial infraction by satyavardhan pharm.d
Myocardial infraction by satyavardhan pharm.d
 
Case presentation on ALD with PORTAL HTN
Case presentation on ALD with PORTAL HTN Case presentation on ALD with PORTAL HTN
Case presentation on ALD with PORTAL HTN
 
Case presentation on hypothyroidism
Case presentation on hypothyroidismCase presentation on hypothyroidism
Case presentation on hypothyroidism
 
CASE PRESENTATION ON DIABETES MELLITUS
CASE PRESENTATION ON DIABETES MELLITUSCASE PRESENTATION ON DIABETES MELLITUS
CASE PRESENTATION ON DIABETES MELLITUS
 
Case presentation on Alcoholic liver disease
Case presentation on Alcoholic liver diseaseCase presentation on Alcoholic liver disease
Case presentation on Alcoholic liver disease
 
case ppt on UTI with IBD
case ppt on UTI with IBDcase ppt on UTI with IBD
case ppt on UTI with IBD
 
Viral hepatitis
Viral hepatitisViral hepatitis
Viral hepatitis
 
14. a case study on diabetes mellitus type 1 with diabetic ketoacidosis cp in...
14. a case study on diabetes mellitus type 1 with diabetic ketoacidosis cp in...14. a case study on diabetes mellitus type 1 with diabetic ketoacidosis cp in...
14. a case study on diabetes mellitus type 1 with diabetic ketoacidosis cp in...
 
case presentation on cOPD
case presentation on cOPDcase presentation on cOPD
case presentation on cOPD
 
Case Studies Clinical pharmacy
Case Studies Clinical pharmacyCase Studies Clinical pharmacy
Case Studies Clinical pharmacy
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 

Similar to Managing Type 2 Diabetes and Related Conditions

Highlights of ADA guidelines 2015 in Diabetes management
Highlights of ADA guidelines 2015 in Diabetes managementHighlights of ADA guidelines 2015 in Diabetes management
Highlights of ADA guidelines 2015 in Diabetes managementAhmed Elmoughazy
 
Caso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaa
Caso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaaCaso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaa
Caso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaaBrunoHernndez16
 
Management of hypertension problems in gp
Management of hypertension problems in gpManagement of hypertension problems in gp
Management of hypertension problems in gpAmir Mahmoud
 
Diabetes mellitus type ii
Diabetes mellitus type iiDiabetes mellitus type ii
Diabetes mellitus type iiIqra Butt
 
preventation of-coronary-vascular-disorders
preventation of-coronary-vascular-disorderspreventation of-coronary-vascular-disorders
preventation of-coronary-vascular-disordersBaqer Aliraqi
 
Metabolic syndrome,obesity
Metabolic syndrome,obesityMetabolic syndrome,obesity
Metabolic syndrome,obesityAli Yousafzai
 
Pediatric Type 2 Diabetes Mellitus. BY DR SAYED ISMAIL
Pediatric Type 2 Diabetes Mellitus. BY  DR SAYED ISMAILPediatric Type 2 Diabetes Mellitus. BY  DR SAYED ISMAIL
Pediatric Type 2 Diabetes Mellitus. BY DR SAYED ISMAILSayed Ahmed
 
KDIGO_Diabetes-in-CKD-Infographics-Set.pdf
KDIGO_Diabetes-in-CKD-Infographics-Set.pdfKDIGO_Diabetes-in-CKD-Infographics-Set.pdf
KDIGO_Diabetes-in-CKD-Infographics-Set.pdfMaiKhairy3
 
metabolic syndrome by dr amber.pptx
metabolic syndrome by dr amber.pptxmetabolic syndrome by dr amber.pptx
metabolic syndrome by dr amber.pptxAmberMushtaq4
 
Diabetes nov2019 om alhamam (1)
Diabetes nov2019 om alhamam (1)Diabetes nov2019 om alhamam (1)
Diabetes nov2019 om alhamam (1)hospital
 
Cardiometabolic syndrome
Cardiometabolic syndromeCardiometabolic syndrome
Cardiometabolic syndromeHossam atef
 
Ada guidelines.pptx
Ada guidelines.pptxAda guidelines.pptx
Ada guidelines.pptxPreethamK15
 
Diabetes Mellitus..part 3
Diabetes Mellitus..part 3Diabetes Mellitus..part 3
Diabetes Mellitus..part 3Pratap Tiwari
 

Similar to Managing Type 2 Diabetes and Related Conditions (20)

Highlights of ADA guidelines 2015 in Diabetes management
Highlights of ADA guidelines 2015 in Diabetes managementHighlights of ADA guidelines 2015 in Diabetes management
Highlights of ADA guidelines 2015 in Diabetes management
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Caso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaa
Caso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaaCaso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaa
Caso clínico hasaaaaaaaaaaaaaaaaaaaaaaaaa
 
Management of hypertension problems in gp
Management of hypertension problems in gpManagement of hypertension problems in gp
Management of hypertension problems in gp
 
Diabetes mellitus type ii
Diabetes mellitus type iiDiabetes mellitus type ii
Diabetes mellitus type ii
 
preventation of-coronary-vascular-disorders
preventation of-coronary-vascular-disorderspreventation of-coronary-vascular-disorders
preventation of-coronary-vascular-disorders
 
Metabolic syndrome,obesity
Metabolic syndrome,obesityMetabolic syndrome,obesity
Metabolic syndrome,obesity
 
Hypertension & Diabetes
Hypertension & DiabetesHypertension & Diabetes
Hypertension & Diabetes
 
Cardiovascular Risk Factors and Hypertension
Cardiovascular Risk Factors and HypertensionCardiovascular Risk Factors and Hypertension
Cardiovascular Risk Factors and Hypertension
 
Pediatric Type 2 Diabetes Mellitus. BY DR SAYED ISMAIL
Pediatric Type 2 Diabetes Mellitus. BY  DR SAYED ISMAILPediatric Type 2 Diabetes Mellitus. BY  DR SAYED ISMAIL
Pediatric Type 2 Diabetes Mellitus. BY DR SAYED ISMAIL
 
KDIGO_Diabetes-in-CKD-Infographics-Set.pdf
KDIGO_Diabetes-in-CKD-Infographics-Set.pdfKDIGO_Diabetes-in-CKD-Infographics-Set.pdf
KDIGO_Diabetes-in-CKD-Infographics-Set.pdf
 
DM+HTN Therapy Goals.pptx
DM+HTN Therapy Goals.pptxDM+HTN Therapy Goals.pptx
DM+HTN Therapy Goals.pptx
 
metabolic syndrome by dr amber.pptx
metabolic syndrome by dr amber.pptxmetabolic syndrome by dr amber.pptx
metabolic syndrome by dr amber.pptx
 
Htn & Diabetes1
Htn & Diabetes1Htn & Diabetes1
Htn & Diabetes1
 
Dkd new look
Dkd new lookDkd new look
Dkd new look
 
Diabetes nov2019 om alhamam (1)
Diabetes nov2019 om alhamam (1)Diabetes nov2019 om alhamam (1)
Diabetes nov2019 om alhamam (1)
 
Cardiometabolic syndrome
Cardiometabolic syndromeCardiometabolic syndrome
Cardiometabolic syndrome
 
DIABETES MELLITUS.pptx
DIABETES MELLITUS.pptxDIABETES MELLITUS.pptx
DIABETES MELLITUS.pptx
 
Ada guidelines.pptx
Ada guidelines.pptxAda guidelines.pptx
Ada guidelines.pptx
 
Diabetes Mellitus..part 3
Diabetes Mellitus..part 3Diabetes Mellitus..part 3
Diabetes Mellitus..part 3
 

More from Joy Awoniyi

Prevention of Venous Thromboembolism
Prevention of Venous ThromboembolismPrevention of Venous Thromboembolism
Prevention of Venous ThromboembolismJoy Awoniyi
 
Basic Pharmacy Calculations and Pharmacokinetes
Basic Pharmacy Calculations and PharmacokinetesBasic Pharmacy Calculations and Pharmacokinetes
Basic Pharmacy Calculations and PharmacokinetesJoy Awoniyi
 
IDSA Practice Guidelines for Antimicrobial Stewardship Programs
IDSA Practice Guidelines for Antimicrobial Stewardship ProgramsIDSA Practice Guidelines for Antimicrobial Stewardship Programs
IDSA Practice Guidelines for Antimicrobial Stewardship ProgramsJoy Awoniyi
 
Journal Club: Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Journal Club: Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary SyndromesJournal Club: Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Journal Club: Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary SyndromesJoy Awoniyi
 
Journal Club - Early versus Late Parenteral Nutrition in Critically Ill Adults
Journal Club - Early versus Late Parenteral Nutrition in Critically Ill AdultsJournal Club - Early versus Late Parenteral Nutrition in Critically Ill Adults
Journal Club - Early versus Late Parenteral Nutrition in Critically Ill AdultsJoy Awoniyi
 
Case Presentation: Management of Hyperparathyroidism following Surgery
Case Presentation: Management of Hyperparathyroidism following SurgeryCase Presentation: Management of Hyperparathyroidism following Surgery
Case Presentation: Management of Hyperparathyroidism following SurgeryJoy Awoniyi
 
Drug Monograph and Literature Review: &quot;Arcapta Neohaler&quot;
Drug Monograph and Literature Review: &quot;Arcapta Neohaler&quot;Drug Monograph and Literature Review: &quot;Arcapta Neohaler&quot;
Drug Monograph and Literature Review: &quot;Arcapta Neohaler&quot;Joy Awoniyi
 
Disease State Presentation: Herpes Simplex Virus
Disease State Presentation: Herpes Simplex VirusDisease State Presentation: Herpes Simplex Virus
Disease State Presentation: Herpes Simplex VirusJoy Awoniyi
 
Journal Club: Fidaxomicin versus Vancomycin for Clostridium Difficile Infection
Journal Club: Fidaxomicin versus Vancomycin for Clostridium Difficile InfectionJournal Club: Fidaxomicin versus Vancomycin for Clostridium Difficile Infection
Journal Club: Fidaxomicin versus Vancomycin for Clostridium Difficile InfectionJoy Awoniyi
 

More from Joy Awoniyi (10)

Prevention of Venous Thromboembolism
Prevention of Venous ThromboembolismPrevention of Venous Thromboembolism
Prevention of Venous Thromboembolism
 
Basic Pharmacy Calculations and Pharmacokinetes
Basic Pharmacy Calculations and PharmacokinetesBasic Pharmacy Calculations and Pharmacokinetes
Basic Pharmacy Calculations and Pharmacokinetes
 
IDSA Practice Guidelines for Antimicrobial Stewardship Programs
IDSA Practice Guidelines for Antimicrobial Stewardship ProgramsIDSA Practice Guidelines for Antimicrobial Stewardship Programs
IDSA Practice Guidelines for Antimicrobial Stewardship Programs
 
Viral Hepatitis
Viral HepatitisViral Hepatitis
Viral Hepatitis
 
Journal Club: Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Journal Club: Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary SyndromesJournal Club: Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Journal Club: Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
 
Journal Club - Early versus Late Parenteral Nutrition in Critically Ill Adults
Journal Club - Early versus Late Parenteral Nutrition in Critically Ill AdultsJournal Club - Early versus Late Parenteral Nutrition in Critically Ill Adults
Journal Club - Early versus Late Parenteral Nutrition in Critically Ill Adults
 
Case Presentation: Management of Hyperparathyroidism following Surgery
Case Presentation: Management of Hyperparathyroidism following SurgeryCase Presentation: Management of Hyperparathyroidism following Surgery
Case Presentation: Management of Hyperparathyroidism following Surgery
 
Drug Monograph and Literature Review: &quot;Arcapta Neohaler&quot;
Drug Monograph and Literature Review: &quot;Arcapta Neohaler&quot;Drug Monograph and Literature Review: &quot;Arcapta Neohaler&quot;
Drug Monograph and Literature Review: &quot;Arcapta Neohaler&quot;
 
Disease State Presentation: Herpes Simplex Virus
Disease State Presentation: Herpes Simplex VirusDisease State Presentation: Herpes Simplex Virus
Disease State Presentation: Herpes Simplex Virus
 
Journal Club: Fidaxomicin versus Vancomycin for Clostridium Difficile Infection
Journal Club: Fidaxomicin versus Vancomycin for Clostridium Difficile InfectionJournal Club: Fidaxomicin versus Vancomycin for Clostridium Difficile Infection
Journal Club: Fidaxomicin versus Vancomycin for Clostridium Difficile Infection
 

Managing Type 2 Diabetes and Related Conditions

  • 1. Joy A. Awoniyi Ambulatory Care Rotation Preceptor: Dr. Daryl Norwood Diabetes Case Presentation R.C is a 57-year-old man with Type 2 diabetes first diagnosed two years ago. Other medical problems include obesity and hypothyroidism. He has a history of heavy alcohol use but quit drinking alcohol 2 years ago. He presents now for routine follow-up and is noted to have a blood pressure of 168/100 mmHg. He is asymptomatic. Physical exam reveals a height of 5’8” (172cm), weight of 243 pounds (110kg), blood pressure of 160/100 mmHg, and a regular pulse of 84 beats per minute. There is no retinopathy or thyromegaly. There is no clinical evidence of congestive heart failure or peripheral vascular disease. Laboratory evaluation reveals trace protein on urinalysis, a low-density lipoprotein (LDL) cholesterol level of 134 mg/dL, a high-density lipoprotein (HDL) cholesterol level of 35mg/dL, a triglyceride level of 460mg/dL and a total cholesterol level of 240 mg/dL, blood urea nitrogen of 14mg/dL, serum creatinine of 1.2mg/dL, random serum glucose of 192 mg/dL, a glycosylated hemoglobin level of 9.5%, normal electrolytes, and normal thyroid- stimulating hormone levels. A 24-hour urine collection reveals a urinary albumin excretion rate of 250mg daily. Subjective and Objective Findings Patient is asymptomatic PMH of alcohol abuse (quit 2 years ago), obesity, and hypothyroidism Pertinent vital signs and Lab Values o Blood Pressure: 168/100 o Regular pulse: 84 bpm o Serum Creatinine: 1.2mg/dL  Creatinine Clearance calculated at 105.6mL/min or 65.7mL/min (Based on ABW and IBW, respectively) o BMI was calculated to be 36.94kg/m2  Possible relation to hypothyroidism o Albumin excretion of 250mg/day (normal levels between 50 and 80mg/24hrs) o LDL: 134 mg/dL Diagnostic Tests: HgA1C of 9.5% Assessment Related Complications o High blood pressure o Dyslipidemia o Nephropathy manifested as proteinuria Risk Factors o Obesity (BMI greater than 25) o A1C >/= 5.7% o Blood pressure >/= 140/90; Hypertension Therapeutic Goals o Tight glycemic control:Reduce A1C to less than 7% without causing hypoglycemia o Prevention of cardiovascular disease Diabetes Case SOAP 1
  • 2.  Goal blood pressure for patients with diabetes is <130/<80  Reduce CVD risks by maintaining healthy cholesterol levels. LDL goal should be <100 No current medications were mentioned. There is a need for therapy in order to lower A1C and manage the patient’s diabetes and related conditions. Plan Further Tests and Work-Up Liver function tests Repeat blood pressure to confirm hypertension CBC to rule out and monitor for infections More detailed history needed o List of medications (current and failed therapies) o Family history o Previous immunizations o Medication Regimen adherence and barriers to adherence Treatment Recommendation: To manage his diabetes, I recommend that the patient be started on Metformin 500mg once daily in addition tothe initiation of lifestyle modifications. This dose may be increased to twice daily dosing as needed or as tolerated every 1-2 weeks with a maximum dose of 2 grams daily. In the management of diabetes for this patient, drugs that may cause the patient to gain weight should be avoided. The patient’s blood pressure should be managed with an ACE Inhibitor such as Lisinopril 10mg daily. Once daily dosing would be ideal and his choice of ACE-inhibitor should be related to the price for the patient as most ACE inhibitors exhibit similar profiles. Hydrochlorothiazide may be added for additional control and numerous preparations are available as combinations of ACE-inhibitors and thiazide diuretics. A beta-blocker is not recommended at this point in therapy due to the masking of hypoglycemia that may accompany a new diabetes regimen. Drug therapy is also recommended for this patient to control cholesterol since the values are above 130. A reduction of LDL to 99 from 134 is a 26.11% reduction. In a comparison evaluating multiple trials with endpoints to reduce cardiovascular disease risks in patients with diabetes, Simvastatin appears to have showed the most benefit in the 4S-DM study where doses between 20 and 40mg daily demonstrated an absolute risk reduction of 42.5% and LDL reduction of 36%. Simvastatin 20mg daily is recommended as initial treatment for this patient. Although diabetics are prone to increase in clot formation, Aspirin daily is not recommended at this point in therapy for this particular patient. He is not as high risk and has no evidence of CHF or peripheral vascular disease. Goals and Monitoring Parameters Metformin use requires routine monitoring of liver function tests and serum creatinine. The urine should also be monitored for glucose and ketones. ACE inhibitor therapy requires monitoring of electrolyte levels (potassium, in particular), blood pressure, renal function, and BUN. Simvastatin use warrants the monitoring of LFTs, as well as Creatinine Kinase, which is indicative of myopathies associated with the medication. 2 Diabetes SOAP Case
  • 3. Joy A. Awoniyi Ambulatory Care Rotation Preceptor: Dr. Daryl Norwood Weight changes should be monitored to assess the need for more aggressive treatments or diet restriction. Monitor Carbohydrate and fat intake. Total fat should be less than 7% of the total calories. Target Levels: o A1C  Less than 7% Monitor every 2-3 months. o Blood pressure  Less than 130/80 Monitor at every routine visit o LDL  Less than 100 Lipid assessments may be repeated every 1-2 years Routine tests should be performed to evaluate the efficacy of therapy as well as to monitor the progression of diabetes to prevent further complications o Eye exams annually o Serum creatinine at least annually o Foot examination o Screening for neuropathies Patient Counseling To reduce GI side effects, take metformin with food. Avoid drinking alcohol. In addition to its contributions to hyperglycemia, alcohol has a negative interaction on the drugs Metformin and Simvastatin that can cause liver toxicities. To achieve adequate control of diabetes, lifestyle modifications are an important part of therapy. Dietary restrictions, increase in physical activity, and gradual weight loss will be more beneficial than taking medication, alone. o Exercise should include aerobic activities, such as swimming, walking, or running, at least 3 days during each week. Diabetes Case SOAP 3